BIOTRON LIMITED - Announcements

0.00%

0.3¢

Market Cap $3.318M

Healthcare Biotechnology

Biotron Limited is a clinical-stage biotechnology company. The Company is engaged in the... Biotron Limited is a clinical-stage biotechnology company. The Company is engaged in the research, development, and commercialization of drugs targeting significant viral diseases with unmet medical need. The Company has BIT225 in clinical development for HIV-1 and COVID-19, and additional preclinical programs including Hepatitis B Virus (HBV). In addition, the Company has several early-stage programs designing drugs that target a class of virus protein known as viroporins, which have a key role in the virus life cycle of a range of viruses, such as Coronavirus, Dengue, Ebola, Middle East Respiratory virus, Influenza and Zika viruses. Its proprietary primary bacterial cell-based screening platform enables rapid screening of target viroporin proteins. Its lead compound, BIT225, is in Phase II development for the treatment of HIV-1. The Company also has a portfolio of preclinical antiviral programs.More

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile

See benefits

Announcements

Filter Results

All Price Sensitive Only

Filters [Clear]

Price Sensitive: Yes

BIT	PRESENTATION OF BIT225-009 HIV-1 PHASE 2 DATA	PRICE SENSITIVE	28/11/18	2.91MB	Share
BIT	Response to ASX aware letter	PRICE SENSITIVE	30/10/18	614.87KB	Share
BIT	Appendix 4C - quarterly	PRICE SENSITIVE	24/10/18	89.58KB	Share
BIT	Biotron Secures $4.7 Million Underwriting Agreement	PRICE SENSITIVE	17/10/18	34.77KB	Share
BIT	$1.07 million R&D Tax Incentive Received	PRICE SENSITIVE	15/10/18	41.34KB	Share
BIT	Significant Immunological Outcomes in BIT225 HIV-1 Trial	PRICE SENSITIVE	28/09/18	406.97KB	Share
BIT	Full Year Statutory Accounts	PRICE SENSITIVE	29/08/18	2.02MB	Share
BIT	Update on Progress of BIT225 Phase 2 HIV-1 Clinical Trial	PRICE SENSITIVE	07/08/18	382.37KB	Share
BIT	Appendix 4C - quarterly	PRICE SENSITIVE	11/07/18	686.82KB	Share
BIT	Response to ASX Appendix 4C Query	PRICE SENSITIVE	10/05/18	986.36KB	Share
BIT	Response to ASX Price Query	PRICE SENSITIVE	10/05/18	630.61KB	Share
BIT	Prospectus	PRICE SENSITIVE	10/05/18	975.11KB	Share
BIT	Renounceable Rights Issue	PRICE SENSITIVE	10/05/18	5.54MB	Share
BIT	Trading Halt	PRICE SENSITIVE	08/05/18	67.26KB	Share
BIT	Appendix 4C - quarterly	PRICE SENSITIVE	24/04/18	686.08KB	Share
BIT	Update on Progress of BIT225 Phase 2 HIV-1 Clinical Trial	PRICE SENSITIVE	06/04/18	456.15KB	Share
BIT	Half Yearly Report and Accounts	PRICE SENSITIVE	23/02/18	322.6KB	Share
BIT	Appendix 4C - quarterly	PRICE SENSITIVE	16/01/18	87.35KB	Share
BIT	Biotron Compounds Demonstrate Activity Against HBV	PRICE SENSITIVE	15/11/17	45.29KB	Share
BIT	$1.6 Million R&D Tax Incentive Received	PRICE SENSITIVE	01/11/17	39.7KB	Share
BIT	Response to ASX Price Query	PRICE SENSITIVE	26/10/17	179.5KB	Share
BIT	Appendix 4C - quarterly	PRICE SENSITIVE	13/10/17	162.75KB	Share
BIT	Full Year Statutory Accounts	PRICE SENSITIVE	28/08/17	585.8KB	Share
BIT	BIT225 Phase 2 HIV-1 Clinical Trial Fully Recruited	PRICE SENSITIVE	27/07/17	36.52KB	Share
BIT	Appendix 4C - quarterly	PRICE SENSITIVE	13/07/17	87.48KB	Share
BIT	BIT225 Phase 2 HIV-1 Clinical Trial Update	PRICE SENSITIVE	15/06/17	45.74KB	Share
BIT	Prospectus	PRICE SENSITIVE	25/05/17	170.89KB	Share
BIT	Renounceable Issue	PRICE SENSITIVE	25/05/17	2.02MB	Share
BIT	Appendix 4C - quarterly	PRICE SENSITIVE	20/04/17	87.41KB	Share
BIT	Update on Progress of BIT225 Phase 2 HIV-1 Clinical Trial	PRICE SENSITIVE	11/04/17	40.14KB	Share
BIT	Half Yearly Report and Accounts	PRICE SENSITIVE	24/02/17	256.06KB	Share
BIT	$1.6 Million R&D Tax Rebate Received	PRICE SENSITIVE	13/02/17	32.75KB	Share
BIT	Commencement of BIT225 Phase 2 HIV-1 Clinical Trial	PRICE SENSITIVE	13/02/17	41.94KB	Share
BIT	BIT225 Accelerates HIV-1 Virus Reduction	PRICE SENSITIVE	06/02/17	36.23KB	Share
BIT	Appendix 4C - quarterly	PRICE SENSITIVE	16/01/17	82.15KB	Share
BIT	Appendix 4C - quarterly-BIT.AX	PRICE SENSITIVE	17/10/16	82.17KB	Share
BIT	Zika Virus Program Update-BIT.AX	PRICE SENSITIVE	22/08/16	79.6KB	Share
BIT	Full Year Statutory Accounts-BIT.AX	PRICE SENSITIVE	05/08/16	428.34KB	Share
BIT	Appendix 4C - quarterly-BIT.AX	PRICE SENSITIVE	08/07/16	22.67KB	Share
BIT	Biotron compounds demonstrate activity against Zika virus-BIT.AX	PRICE SENSITIVE	23/05/16	98.76KB	Share
BIT	$1.5 Million R&D Tax Rebate-BIT.AX	PRICE SENSITIVE	20/04/16	34.13KB	Share
BIT	Appendix 4C - quarterly-BIT.AX	PRICE SENSITIVE	20/04/16	22.69KB	Share
BIT	Phase 2 Hepatitis C Trial Success	PRICE SENSITIVE	17/03/16	26.86KB	Share
BIT	Half Yearly Report and Accounts	PRICE SENSITIVE	26/02/16	107.47KB	Share
BIT	BIT225 MAY HAVE A BROADER ROLE IN LIMITING HIV-1 INFECTION	PRICE SENSITIVE	18/02/16	36.42KB	Share
BIT	BIOTRON COMPOUNDS TESTED FOR ACTIVITY AGAINST ZIKA VIRUS	PRICE SENSITIVE	16/02/16	22.68KB	Share
BIT	Appendix 4C - quarterly	PRICE SENSITIVE	15/01/16	22.71KB	Share
BIT	Appendix 4C - quarterly	PRICE SENSITIVE	22/10/15	37.74KB	Share
BIT	INTERIM HCV GENOTYPE 3 DATA FROM BIT225-008 STUDY	PRICE SENSITIVE	30/09/15	31.61KB	Share
BIT	Annual Report to Shareholders	PRICE SENSITIVE	28/08/15	363.33KB	Share
BIT	Cash Flow Report	PRICE SENSITIVE	27/07/15	47.21KB	Share
BIT	Independent review supports development of BIT225	PRICE SENSITIVE	06/07/15	25.16KB	Share
BIT	Share Purchase Plan and Placement to Raise $4.0 Million	PRICE SENSITIVE	18/06/15	339.09KB	Share
BIT	Trading Halt	PRICE SENSITIVE	16/06/15	42.19KB	Share
BIT	Appendix 4C - quarterly	PRICE SENSITIVE	24/04/15	37.76KB	Share
BIT	R&D Tax Incentive	PRICE SENSITIVE	21/04/15	48.72KB	Share
BIT	Update on Phase 2 Trial and IND Progress	PRICE SENSITIVE	17/04/15	40.79KB	Share
BIT	Half Yearly Report and Accounts	PRICE SENSITIVE	27/02/15	112.08KB	Share
BIT	Response to ASX price query	PRICE SENSITIVE	26/02/15	111.4KB	Share
BIT	Appendix 4C - quarterly	PRICE SENSITIVE	21/01/15	37.77KB	Share
BIT	Response to ASX Price Query	PRICE SENSITIVE	08/01/15	117.33KB	Share
BIT	Enrolment of Phase 2 Hepatitis C Trial of BIT225 Completed	PRICE SENSITIVE	03/12/14	26.74KB	Share
BIT	Appendix 4C - quarterly	PRICE SENSITIVE	31/10/14	37.7KB	Share
BIT	Rights Issue Prospectus	PRICE SENSITIVE	15/10/14	1.69MB	Share
BIT	Fully Underwritten Rights Issue and Investor Presentation	PRICE SENSITIVE	15/10/14	2.31MB	Share
BIT	Trading halt	PRICE SENSITIVE	13/10/14	46.2KB	Share
BIT	BIT225 TRIAL RESULTS SHOW EFFECTIVE CURE OF HEPATITIS C	PRICE SENSITIVE	10/10/14	55.29KB	Share
BIT	Annual Report to Shareholders	PRICE SENSITIVE	28/08/14	388.98KB	Share
BIT	Appendix 4C - quarterly	PRICE SENSITIVE	24/07/14	37.75KB	Share
BIT	BIT225 Reverses HIV-Induced Impairment of the Immune System	PRICE SENSITIVE	23/07/14	792.76KB	Share
BIT	Response to ASX price query	PRICE SENSITIVE	06/06/14	78.98KB	Share
BIT	BIT225 HCV Trial Update - Thailand	PRICE SENSITIVE	23/05/14	41.72KB	Share
BIT	Appendix 4C - quarterly	PRICE SENSITIVE	24/04/14	73.92KB	Share
BIT	$1.7 Million R&D Tax Incentive Refund	PRICE SENSITIVE	04/04/14	49.09KB	Share
BIT	Update on BIT225 HCV Program	PRICE SENSITIVE	11/03/14	54KB	Share
BIT	BIT225 HIV/HCV TRIAL PATIENTS VIRUS FREE AT SIX MONTHS	PRICE SENSITIVE	06/03/14	54.55KB	Share
BIT	Half Yearly Report and Accounts	PRICE SENSITIVE	21/02/14	116.45KB	Share
BIT	Key USA Patent Allowed for Biotron's BIT225	PRICE SENSITIVE	13/02/14	54.23KB	Share
BIT	Response to ASX query	PRICE SENSITIVE	23/01/14	86.74KB	Share
BIT	Appendix 4C - quarterly	PRICE SENSITIVE	21/01/14	37.71KB	Share
BIT	Presentation of HIV Data at HIV Persistence Meeting	PRICE SENSITIVE	05/12/13	282.82KB	Share
BIT	Independent Research Validates Biotron HCV Drug Candidate	PRICE SENSITIVE	27/11/13	53.94KB	Share
BIT	Ethics Approval for Three Month HCV Trial	PRICE SENSITIVE	21/11/13	59.15KB	Share
BIT	HCV/HIV Trial Data Presented to International Conference	PRICE SENSITIVE	06/11/13	822.72KB	Share
BIT	ANTIVIRAL ACTIVITY ENHANCED IN HIV/HCV GENOTYPE 3 PATIENTS	PRICE SENSITIVE	25/10/13	49.49KB	Share
BIT	Appendix 4C - quarterly	PRICE SENSITIVE	21/10/13	37.66KB	Share
BIT	Annual Report to shareholders	PRICE SENSITIVE	28/08/13	240.81KB	Share
BIT	BIT225 Capsule Formulation Trial Completed	PRICE SENSITIVE	14/08/13	93.96KB	Share
BIT	Patient Enrolment in Phase 2 Co-Infected Study Completed	PRICE SENSITIVE	31/07/13	108.16KB	Share
BIT	Appendix 4C - quarterly	PRICE SENSITIVE	26/07/13	37.72KB	Share
BIT	Presentation of HIV Trial Data to International AIDS Society	PRICE SENSITIVE	01/07/13	2.81MB	Share
BIT	R&D Tax Incentive Refund	PRICE SENSITIVE	31/05/13	33.21KB	Share
BIT	Appendix 4C - quarterly	PRICE SENSITIVE	30/04/13	37.71KB	Share
BIT	HIV TRIAL VALIDATES NOVEL DRUG MECHANISM	PRICE SENSITIVE	19/03/13	54.49KB	Share
BIT	Half Yearly Report and Accounts	PRICE SENSITIVE	27/02/13	173.99KB	Share
BIT	Appendix 4C - quarterly	PRICE SENSITIVE	17/01/13	37.7KB	Share
BIT	Biotron Completes Clinical Stage of HIV Clinical Trial	PRICE SENSITIVE	14/12/12	49.29KB	Share
BIT	Commencement of Three-Month Toxicology Studies For BIT225	PRICE SENSITIVE	27/11/12	48.93KB	Share
BIT	Presentation of BIT225 HCV 48-week data at AASLD Conference	PRICE SENSITIVE	16/11/12	961.96KB	Share
BIT	Key Phase 2 HIV/HCV Trial Commenced	PRICE SENSITIVE	09/11/12	50.25KB	Share

BIT PRESENTATION OF BIT225-009 HIV-1 PHASE 2 DATA
28/11/18	PRICE SENSITIVE	2.91MB	Share
BIT Response to ASX aware letter
30/10/18	PRICE SENSITIVE	614.87KB	Share
BIT Appendix 4C - quarterly
24/10/18	PRICE SENSITIVE	89.58KB	Share
BIT Biotron Secures $4.7 Million Underwriting Agreement
17/10/18	PRICE SENSITIVE	34.77KB	Share
BIT $1.07 million R&D Tax Incentive Received
15/10/18	PRICE SENSITIVE	41.34KB	Share
BIT Significant Immunological Outcomes in BIT225 HIV-1 Trial
28/09/18	PRICE SENSITIVE	406.97KB	Share
BIT Full Year Statutory Accounts
29/08/18	PRICE SENSITIVE	2.02MB	Share
BIT Update on Progress of BIT225 Phase 2 HIV-1 Clinical Trial
07/08/18	PRICE SENSITIVE	382.37KB	Share
BIT Appendix 4C - quarterly
11/07/18	PRICE SENSITIVE	686.82KB	Share
BIT Response to ASX Appendix 4C Query
10/05/18	PRICE SENSITIVE	986.36KB	Share
BIT Response to ASX Price Query
10/05/18	PRICE SENSITIVE	630.61KB	Share
BIT Prospectus
10/05/18	PRICE SENSITIVE	975.11KB	Share
BIT Renounceable Rights Issue
10/05/18	PRICE SENSITIVE	5.54MB	Share
BIT Trading Halt
08/05/18	PRICE SENSITIVE	67.26KB	Share
BIT Appendix 4C - quarterly
24/04/18	PRICE SENSITIVE	686.08KB	Share
BIT Update on Progress of BIT225 Phase 2 HIV-1 Clinical Trial
06/04/18	PRICE SENSITIVE	456.15KB	Share
BIT Half Yearly Report and Accounts
23/02/18	PRICE SENSITIVE	322.6KB	Share
BIT Appendix 4C - quarterly
16/01/18	PRICE SENSITIVE	87.35KB	Share
BIT Biotron Compounds Demonstrate Activity Against HBV
15/11/17	PRICE SENSITIVE	45.29KB	Share
BIT $1.6 Million R&D Tax Incentive Received
01/11/17	PRICE SENSITIVE	39.7KB	Share
BIT Response to ASX Price Query
26/10/17	PRICE SENSITIVE	179.5KB	Share
BIT Appendix 4C - quarterly
13/10/17	PRICE SENSITIVE	162.75KB	Share
BIT Full Year Statutory Accounts
28/08/17	PRICE SENSITIVE	585.8KB	Share
BIT BIT225 Phase 2 HIV-1 Clinical Trial Fully Recruited
27/07/17	PRICE SENSITIVE	36.52KB	Share
BIT Appendix 4C - quarterly
13/07/17	PRICE SENSITIVE	87.48KB	Share
BIT BIT225 Phase 2 HIV-1 Clinical Trial Update
15/06/17	PRICE SENSITIVE	45.74KB	Share
BIT Prospectus
25/05/17	PRICE SENSITIVE	170.89KB	Share
BIT Renounceable Issue
25/05/17	PRICE SENSITIVE	2.02MB	Share
BIT Appendix 4C - quarterly
20/04/17	PRICE SENSITIVE	87.41KB	Share
BIT Update on Progress of BIT225 Phase 2 HIV-1 Clinical Trial
11/04/17	PRICE SENSITIVE	40.14KB	Share
BIT Half Yearly Report and Accounts
24/02/17	PRICE SENSITIVE	256.06KB	Share
BIT $1.6 Million R&D Tax Rebate Received
13/02/17	PRICE SENSITIVE	32.75KB	Share
BIT Commencement of BIT225 Phase 2 HIV-1 Clinical Trial
13/02/17	PRICE SENSITIVE	41.94KB	Share
BIT BIT225 Accelerates HIV-1 Virus Reduction
06/02/17	PRICE SENSITIVE	36.23KB	Share
BIT Appendix 4C - quarterly
16/01/17	PRICE SENSITIVE	82.15KB	Share
BIT Appendix 4C - quarterly-BIT.AX
17/10/16	PRICE SENSITIVE	82.17KB	Share
BIT Zika Virus Program Update-BIT.AX
22/08/16	PRICE SENSITIVE	79.6KB	Share
BIT Full Year Statutory Accounts-BIT.AX
05/08/16	PRICE SENSITIVE	428.34KB	Share
BIT Appendix 4C - quarterly-BIT.AX
08/07/16	PRICE SENSITIVE	22.67KB	Share
BIT Biotron compounds demonstrate activity against Zika virus-BIT.AX
23/05/16	PRICE SENSITIVE	98.76KB	Share
BIT $1.5 Million R&D Tax Rebate-BIT.AX
20/04/16	PRICE SENSITIVE	34.13KB	Share
BIT Appendix 4C - quarterly-BIT.AX
20/04/16	PRICE SENSITIVE	22.69KB	Share
BIT Phase 2 Hepatitis C Trial Success
17/03/16	PRICE SENSITIVE	26.86KB	Share
BIT Half Yearly Report and Accounts
26/02/16	PRICE SENSITIVE	107.47KB	Share
BIT BIT225 MAY HAVE A BROADER ROLE IN LIMITING HIV-1 INFECTION
18/02/16	PRICE SENSITIVE	36.42KB	Share
BIT BIOTRON COMPOUNDS TESTED FOR ACTIVITY AGAINST ZIKA VIRUS
16/02/16	PRICE SENSITIVE	22.68KB	Share
BIT Appendix 4C - quarterly
15/01/16	PRICE SENSITIVE	22.71KB	Share
BIT Appendix 4C - quarterly
22/10/15	PRICE SENSITIVE	37.74KB	Share
BIT INTERIM HCV GENOTYPE 3 DATA FROM BIT225-008 STUDY
30/09/15	PRICE SENSITIVE	31.61KB	Share
BIT Annual Report to Shareholders
28/08/15	PRICE SENSITIVE	363.33KB	Share
BIT Cash Flow Report
27/07/15	PRICE SENSITIVE	47.21KB	Share
BIT Independent review supports development of BIT225
06/07/15	PRICE SENSITIVE	25.16KB	Share
BIT Share Purchase Plan and Placement to Raise $4.0 Million
18/06/15	PRICE SENSITIVE	339.09KB	Share
BIT Trading Halt
16/06/15	PRICE SENSITIVE	42.19KB	Share
BIT Appendix 4C - quarterly
24/04/15	PRICE SENSITIVE	37.76KB	Share
BIT R&D Tax Incentive
21/04/15	PRICE SENSITIVE	48.72KB	Share
BIT Update on Phase 2 Trial and IND Progress
17/04/15	PRICE SENSITIVE	40.79KB	Share
BIT Half Yearly Report and Accounts
27/02/15	PRICE SENSITIVE	112.08KB	Share
BIT Response to ASX price query
26/02/15	PRICE SENSITIVE	111.4KB	Share
BIT Appendix 4C - quarterly
21/01/15	PRICE SENSITIVE	37.77KB	Share
BIT Response to ASX Price Query
08/01/15	PRICE SENSITIVE	117.33KB	Share
BIT Enrolment of Phase 2 Hepatitis C Trial of BIT225 Completed
03/12/14	PRICE SENSITIVE	26.74KB	Share
BIT Appendix 4C - quarterly
31/10/14	PRICE SENSITIVE	37.7KB	Share
BIT Rights Issue Prospectus
15/10/14	PRICE SENSITIVE	1.69MB	Share
BIT Fully Underwritten Rights Issue and Investor Presentation
15/10/14	PRICE SENSITIVE	2.31MB	Share
BIT Trading halt
13/10/14	PRICE SENSITIVE	46.2KB	Share
BIT BIT225 TRIAL RESULTS SHOW EFFECTIVE CURE OF HEPATITIS C
10/10/14	PRICE SENSITIVE	55.29KB	Share
BIT Annual Report to Shareholders
28/08/14	PRICE SENSITIVE	388.98KB	Share
BIT Appendix 4C - quarterly
24/07/14	PRICE SENSITIVE	37.75KB	Share
BIT BIT225 Reverses HIV-Induced Impairment of the Immune System
23/07/14	PRICE SENSITIVE	792.76KB	Share
BITResponse to ASX price query
06/06/14	PRICE SENSITIVE	78.98KB	Share
BITBIT225 HCV Trial Update - Thailand
23/05/14	PRICE SENSITIVE	41.72KB	Share
BITAppendix 4C - quarterly
24/04/14	PRICE SENSITIVE	73.92KB	Share
BIT$1.7 Million R&D Tax Incentive Refund
04/04/14	PRICE SENSITIVE	49.09KB	Share
BITUpdate on BIT225 HCV Program
11/03/14	PRICE SENSITIVE	54KB	Share
BITBIT225 HIV/HCV TRIAL PATIENTS VIRUS FREE AT SIX MONTHS
06/03/14	PRICE SENSITIVE	54.55KB	Share
BITHalf Yearly Report and Accounts
21/02/14	PRICE SENSITIVE	116.45KB	Share
BITKey USA Patent Allowed for Biotron's BIT225
13/02/14	PRICE SENSITIVE	54.23KB	Share
BITResponse to ASX query
23/01/14	PRICE SENSITIVE	86.74KB	Share
BITAppendix 4C - quarterly
21/01/14	PRICE SENSITIVE	37.71KB	Share
BITPresentation of HIV Data at HIV Persistence Meeting
05/12/13	PRICE SENSITIVE	282.82KB	Share
BITIndependent Research Validates Biotron HCV Drug Candidate
27/11/13	PRICE SENSITIVE	53.94KB	Share
BITEthics Approval for Three Month HCV Trial
21/11/13	PRICE SENSITIVE	59.15KB	Share
BITHCV/HIV Trial Data Presented to International Conference
06/11/13	PRICE SENSITIVE	822.72KB	Share
BITANTIVIRAL ACTIVITY ENHANCED IN HIV/HCV GENOTYPE 3 PATIENTS
25/10/13	PRICE SENSITIVE	49.49KB	Share
BITAppendix 4C - quarterly
21/10/13	PRICE SENSITIVE	37.66KB	Share
BITAnnual Report to shareholders
28/08/13	PRICE SENSITIVE	240.81KB	Share
BITBIT225 Capsule Formulation Trial Completed
14/08/13	PRICE SENSITIVE	93.96KB	Share
BITPatient Enrolment in Phase 2 Co-Infected Study Completed
31/07/13	PRICE SENSITIVE	108.16KB	Share
BITAppendix 4C - quarterly
26/07/13	PRICE SENSITIVE	37.72KB	Share
BITPresentation of HIV Trial Data to International AIDS Society
01/07/13	PRICE SENSITIVE	2.81MB	Share
BITR&D Tax Incentive Refund
31/05/13	PRICE SENSITIVE	33.21KB	Share
BITAppendix 4C - quarterly
30/04/13	PRICE SENSITIVE	37.71KB	Share
BITHIV TRIAL VALIDATES NOVEL DRUG MECHANISM
19/03/13	PRICE SENSITIVE	54.49KB	Share
BITHalf Yearly Report and Accounts
27/02/13	PRICE SENSITIVE	173.99KB	Share
BITAppendix 4C - quarterly
17/01/13	PRICE SENSITIVE	37.7KB	Share
BITBiotron Completes Clinical Stage of HIV Clinical Trial
14/12/12	PRICE SENSITIVE	49.29KB	Share
BITCommencement of Three-Month Toxicology Studies For BIT225
27/11/12	PRICE SENSITIVE	48.93KB	Share
BITPresentation of BIT225 HCV 48-week data at AASLD Conference
16/11/12	PRICE SENSITIVE	961.96KB	Share
BITKey Phase 2 HIV/HCV Trial Commenced
09/11/12	PRICE SENSITIVE	50.25KB	Share

REFRESH

First 2

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

(20min delay)
Last 0.3¢		Change 0.000(0.00%)		Mkt cap ! $3.318M

Open	High	Low	Value	Volume
0.3¢	0.3¢	0.3¢	$1.538K	615K

Buyers (Bids)

No.	Vol.	Price($)
56	49266483	0.2¢

Sellers (Offers)

Price($)	Vol.	No.
0.3¢	15381642	24

View Market Depth

No.	Vol.	Price($)
56	49266483	0.002
30	73392000	0.001
0	0	0.000
0	0	0.000
0	0	0.000

Price($)	Vol.	No.
0.003	15381642	24
0.004	12320414	15
0.005	6690600	5
0.006	1200000	2
0.007	574234	2

Last trade - 15.14pm 12/08/2025 (20 minute delay)


Last 0.3¢		Change 0.000 ( 0.00 %)
Open	High	Low	Volume
0.3¢	0.3¢	0.3¢	270000
Last updated 10.25am 12/08/2025 ?

BIT (ASX) Chart

BIOTRON LIMITED - Announcements

Corporate SpotlightNot Yet Available

Announcements

Buyers (Bids)

Sellers (Offers)

Top Stories

Corporate Spotlight
Not Yet Available